Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.
JP Morgan Initiates Coverage On Alignment Healthcare with Overweight Rating, Announces Price Target of $20
JP Morgan analyst Lisa Gill initiates coverage on Alignment Healthcare (NASDAQ:ALHC) with a Overweight rating and announces Price Target of $20.